A B S T R AC T
Background. Patients with end-stage renal disease (ESRD) have increased fasting concentrations and disturbed postprandial responses of several glucoregulatory hormones. We aimed to evaluate the impact of high-flux haemodialysis (HD) and high-volume haemodiafiltration (HDF) on fasting and postprandial plasma levels of glucoregulatory pancreatic and gut peptide hormones in ESRD patients. Methods. Ten non-diabetic HD-treated ESRD patients were included to undergo a 3-h standardized liquid mixed meal test 1 h into an HD and an HDF, respectively. On a third, optional, examination day, the meal test was performed without concurrent dialysis treatment. Concentrations of glucose, C-peptide, insulin, glucagon, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide were measured in plasma and dialysate. Results. Ten participants completed the meal test during HD, eight completed the meal test during HDF and four completed the optional meal test without dialysis. All plasma hormone concentrations declined significantly during the first fasting hour of dialysis with no differences between HD and HDF. Significant clearance of the investigated hormones was observed for both dialysis modalities with significantly higher clearance of insulin, C-peptide and GIP during HDF compared with HD. The fractional appearance of hormones entering the utilized dialysate was higher during HDF. Both dialysis modalities reduced postprandial plasma hormone concentrations in a similar manner. Conclusions. Our findings show that HD and HDF, respectively, significantly remove glucoregulatory peptide hormones from plasma of non-diabetic ESRD patients; a phenomenon which may affect the glucose metabolism in dialysis-treated ESRD patients.
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I N T R O D U C T I O N
Glucometabolic disturbances are frequent pathological findings in patients with end-stage renal disease (ESRD). Although often attributed to diabetes, the leading cause of ESRD [1, 2] , some of these disturbances are also present in non-diabetic patients with ESRD. Thus, elevated fasting concentrations and abnormal postprandial responses of important glucoregulatory peptide hormones including insulin, glucagon and the two gut incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have been observed in non-diabetic dialysis-treated ESRD patients [3, 4] . These perturbations may contribute to the high risk of pre-diabetes and cardiovascular disease associated with ESRD. The impact of dialysis on glucometabolic disturbances in ESRD patients has been investigated to some extent. Interestingly, dialysis seems to ameliorate the insulin resistance characterizing ESRD patients, and to cause a substantial removal of circulating insulin [5] [6] [7] [8] . In contrast to insulin, the effect of dialysis on circulating levels of the other pancreatic glucoregulatory hormone glucagon and on the gut incretin hormones in ESRD patients remain to be established. The extent of any dialysis-mediated removal of these hormones is difficult to predict due to the differences in molecular structure, electrochemical properties, protein binding and compartmentalization. Nevertheless, the continuing optimization of dialysis techniques places important glucoregulatory peptides such as glucagon, GLP-1 and GIP [with molecular weights (MW) less than insulin] at risk of substantial removal during dialysis treatment [9] .
In the present study, we aimed to evaluate the impact of highflux haemodialysis (HD) and high-volume haemodiafiltration (HDF) on fasting and postprandial plasma levels of pancreatic (insulin and glucagon) and gut (GIP and GLP-1) glucoregulatory peptide hormones in non-diabetic ESRD patients.
M AT E R I A L S A N D M E T H O D S

Study protocol
The study protocol was approved by the Scientific-Ethical Committee of the Capital Region of Denmark (H-2-2012-171) and by the Danish Data Protection Agency (2007-58-0015) and was registered with ClinicalTrials.gov (NTC01800188). Written informed consent was obtained from all participants before inclusion and the study was conducted according to the latest revision of the Helsinki Declaration.
Sample size
Power calculations were done using insulin and C-peptide as larger and smaller peptide markers (5808 and 3020 Da, respectively). With a significance level of 5% and a power of 80%, 10 patients undergoing an HD with a blood flow of 300 mL/min and a negligible ultrafiltration results in detectable clearances of 35 mmol/L (C-peptide) and 79 mL/min (insulin). With the same statistical parameters, 10 patients undergoing HD and HDF results in detectable differences of 9% (C-peptide) and 23% (insulin) between the two dialysis modalities.
Subjects
Ten patients with ESRD were recruited from the dialysis centres of the Department of Nephrology at Rigshospitalet. Participants fulfilled the following inclusion criteria: age between 18 and 90 years, chronic (minimum 3 months) HD or HDF treatment and a well-functioning arterio-venous fistula with a minimum fistula flow of 400 mL/min. Exclusion criteria included diabetes, impaired fasting glucose (≥6.1 mmol/L), previous bowel resection, inflammatory bowel disease, malignancy, daily intake of medication known to influence glucose metabolism (including oral glucocorticoids and cyclosporine), severe anaemia (blood haemoglobin <6.0 mmol/L) and severe acidosis (total plasma CO 2 <20 mmol/L).
Study design and experimental procedures
A standardized liquid mixed meal test was performed at 2 separate examination days during HD and HDF, respectively. A third meal test without dialysis was optional to the participants. At all examination days, participants were examined after a 10-h overnight fast with no alcohol consumption or vigorous physical activities 24 h before the examination. The liquid meal [250 mL Renilon 4.0 (Nutricia, Denmark), 500 kcal (59 g carbohydrate, 25 g fat and 10 g protein)] was ingested over 5 min 1 h into the dialysis sessions.
Blood and dialysate samples. Baseline blood samples (Time 0) were collected from the fistula prior to initiation of the dialysis. During the dialysis sessions, blood samples were drawn from the arterial line of the dialyser at Time 30, 60 (prior to meal), 75, 90, 120, 150, 180, 210 and 240 min. Furthermore, samples were collected from the venous line of the dialyser and dialysate at Time 60, 120, 180 and 240 min. To be able to evaluate clearance during high efficient dialysis, blood samples were drawn without reducing the blood flow except when measuring dialysis access recirculation evaluated by the three sampling low-flow method using urea as a solute marker [10] . During the meal test without dialysis, blood samples were also drawn from the arterio-venous fistula at the same time intervals as during the dialysis sessions. Blood and dialysate samples for plasma GLP-1, GIP and glucagon were collected in chilled EDTA tubes containing a DPP-4 inhibitor (valine-pyrrolidide, final concentration = 0.01 mmol/ L). All blood samples were centrifuged immediately for 20 min at 1200 g and 4°C. Plasma was frozen to and stored at −20°C for subsequent en bloc analysis.
Dialysis treatments. Both dialysis treatments were standardized to 4-h sessions with the same high-flux dialysis filters (Polyflux™210H, Gambro, Sweden), a dialysate flow of 500 mL/min and no sodium or ultrafiltration profiles allowed. To prevent recirculation, the blood flow was set to a maximum of half of the access flow in the arterio-venous fistula and kept constant throughout the dialysis session. The same blood flow was used at the two dialysis sessions. The HDF used post dilution technique with a constant total ultrafiltration rate set at 25% of the blood flow.
Before initiation of both dialysis sessions blood samples were drawn and immediately analysed for sodium, standard bicarbonate and ionized calcium. The dialysate concentrations of sodium and standard bicarbonate were set accordingly and the ionized calcium concentration of either 1.25 or 1.50 mmol/L was chosen to mirror the fasting value.
Anticoagulation was achieved with low molecular weight heparin (Innohep ® , LEO Pharma Nordic, Sweden) dosed individually although with the same amount at each dialysis session. Dialysis treatments were performed on AK 200™ ULTRA S, dialysis machine (Gambro, Sweden). Fresh dialysate contained 2.0 mmol/L potassium, 0.5 mmol/L magnesium, 3.0 mmol/L acetate and 5.6 mmol/L glucose.
Analysis. Plasma glucose was measured using the glucose oxidase method (YSI 2300 STAT Plus™ Glucose Analyzer, OH, USA). Serum C-peptide and insulin were measured using a sandwich electrochemiluminescence immunoassay method [Elecsys, Roche Diagnostics GmbH, Germany; maximum combined intra-and inter-assay variability 8% (C-peptide), 5% (insulin) and detection limit 3 pmol/L (C-peptide) and 2 pmol/L (insulin)]. Plasma GLP-1 was assayed using an antiserum that reacts equally with intact GLP-1 and the Nterminally truncated metabolite (intra-assay variability <8%, inter-assay variability <16% and detection limit <5 pmol/L) [11] . Plasma GIP was assayed using the C-terminally directed antiserum 867, which reacts fully with intact GIP and GIP(3-42) (intra-assay variability 6% and detection limit <2 pmol/L) [12] . Glucagon analyses were performed as previously described (intra-assay variability <6%, inter-assay variability <15% and detection limit <2 pmol/L) [13] . In order to compare solute concentrations from blood and dialysate analyses, all blood samples were corrected for a water fraction of 93% [14] .
Calculations and statistical analysis
Removal, clearance and appearance of C-peptide, insulin, GLP-1 and GIP during dialysis were evaluated 1 hour after ingestion of the meal (120 min), while glucagon was evaluated just prior to meal ingestion (60 min). In addition, the removal and clearance of C-peptide and insulin were evaluated at 60, 180 and 240 min.
Fractional removal from blood. The fraction of solute removed in respect to solute entering the dialyser, i.e. the fractional removal (FR) was calculated as the difference in solute concentration across the dialyser with respect to the concentration entering the dialyser:
where C A is the solute concentration at the arterial side and C V is the solute concentration at the venous side.
Clearance. Clearance was calculated using the effective plasma/serum water flow:
where Q B is the blood flow in mL/min, HTC is the haematocrit, C A is the solute concentration at the arterial side, C V is the solute concentration at the venous side and Q uf is the ultrafiltration in mL/min.
Fractional appearance in dialysate. The fraction of solute measured in dialysate in respect to solute entering the dialyser, i.e. the fractional appearance (FA) was calculated by the following formula:
where Q D is the dialysate flow in mL/min, C D is the solute concentration in the dialysate, Q uf is the ultrafiltration in mL/min, Q B is the blood flow in mL/min, HTC is the haematocrit and C A is the solute concentration at the arterial side.
Statistical analysis
Analyses were performed using linear mixed models with examination day, repeated measures during the examination day and their interaction as fixed effects and each subject as a random effect. The repeated measures during the examination days were modelled with an ante-dependent covariance structure allowing both heterogeneous variances and heterogeneous correlations between measurements. The distribution was assessed by graphical evaluation of the residuals showing biomarkers to follow a log-normal distribution. Subsequently, all biochemical markers were logarithmic transformed prior to analysis and results were back-transformed. As a consequence, differences between concentrations are expressed in relative units. Simple comparisons were done using t-or F-tests where appropriate and multiple comparisons between the 3 examination days were adjusted using the Tukey-Kramer method. Results are expressed as estimated means or estimated geometric means with 95% confidence intervals unless otherwise stated. P values <0.05 were considered significant.
R E S U LT S
Ten patients were included in the study. Two withdrew following the first examination day, i.e. 10 participants completed the meal test during HD, 8 completed the meal test during HDF and 4 the optional meal test.
Patient characteristics and fasting values
Patients included were predominantly normal weight male Caucasians. Six participants had a diuresis below 400 mL/day and only one participant had residual urine output with no need of ultrafiltration during dialysis. All patients had a fistula flow above 600 mL/min, i.e. blood flow exceeded 300 mL/min during examinations. Hence, all HDFs were high-volume with total ultrafiltration exceeding 20 L/dialysis. Recirculation was not detectable and within a range of ±6%. Participant's demographical, clinical and biochemical characteristics are shown in Table 1 . There were no significant differences in fasting values of plasma glucose or peptides between the different examination days.
Pre-and post-meal concentrations During the first fasting hour of the dialysis sessions (HD and HDF), mean glucose concentrations did not change from fasting values (P > 0.236). In the same time interval, Cpeptide, insulin and glucagon showed highly significant (P < 0.0001) declines in concentrations ranging from 34.3 to 46.0% with respect to concentrations before initiating dialysis (Time 0 min). The decline in GLP-1 and GIP concentrations were less pronounced although all significant (P < 0.05). Glucagon concentration was reduced significantly more during HDF compared with HD (P = 0.014), whereas the two dialysis modalities had similar effect on the remaining parameters. Changes in hormone concentrations during dialysis are presented in Table 2 .
Following the liquid meal, the concentrations of all solutes were significantly (P < 0.038) lower during both HD and HDF compared with the meal test without dialysis except for glucose at the HDF day (P = 0.077). The concentrations of Cpeptide and glucagon were furthermore significantly lower during HDF compared with HD (C-peptide 26.0% lower, P = 0.005 and glucagon 22.1% lower, P = 0.002). See Table 3 and Figure 1A -F. Removal, clearance and appearance Both HD and HDF resulted in significant FR across the dialyser membrane for all the peptides (P < 0.001) except GLP-1, which was borderline significant (P = 0.058 and P = 0.054, respectively). The FR was significantly higher for C-peptide and GIP during HDF (P < 0.001 and P = 0.035, respectively) and also insulin when including measurements at Time 60, 180 and 240 min (P < 0.001). During dialysis sessions, the removal fractions of C-peptide and insulin did not show any statistically significant changes (P > 0.158).
Both HD and HDF resulted in significant clearance of all the investigated peptides (P ≤ 0.012). The estimated clearances were significantly higher during HDF for C-peptide and total GIP (P < 0.001 and P = 0.022, respectively) and also insulin when including measurements at Time 60, 180 and 240 min (P < 0.001). During dialysis sessions the clearance of both Cpeptide and insulin did not show any statistical significant changes (P > 0.059) although a tendency of a decline in insulin clearance of 20 mL/min during HDF was observed.
C-peptide, insulin, glucagon, GLP-1 and GIP were all detected in the utilized dialysate. FR, clearance and FA of the peptides are presented in Table 4 .
D I S C U S S I O N
We show that HD and HDF, respectively, result in reductions in fasting and postprandial plasma concentrations of important pancreatic and gut glucoregulatory peptide hormones in non- 
O R I G I N A L A R T I C L E
C l e a r a n c e o f g l u c o r e g u l a t o r y p e p t i d e s d u r i n g h a e m o d i a l y s i s diabetic ESRD patients due to removal across the dialyser membrane with substantial hormone fractions entering the dialysate.
Most previous studies on the removal of glucoregulatory peptide hormones during dialysis were performed several decades ago with dialysis technologies very different from the presently used. Membrane pore size, surface area and structural design as well as convective dialysis modalities such as HDF have all been optimized throughout the years. In accordance, early studies have shown divergent effects of dialysis on the plasma concentrations of insulin, glucagon and GIP [15] [16] [17] [18] [19] .
In the present study, we investigated the impact of highflux HD and high-volume HDF, respectively, on plasma concentrations of the glucometabolic hormones insulin, C-peptide, glucagon, GLP-1 and GIP. Plasma levels of insulin and glucagon are well-known determinants of fasting plasma glucose levels and plasma glucose excursions following a meal, respectively. Also, during the last couple of decades, it has become increasingly recognized that postprandial release of the gut incretin hormones GLP-1 and GIP plays a pivotal role in controlling postprandial glucose levels. Therefore, we evaluated the effect of HD and HDF, respectively, during the fasting state and in the post-absorptive state after a meal. By ensuring a high fistula-to-blood flow ratio, it was possible to measure clearance during high efficient dialysis. Furthermore, we standardized the dialyses in respect to several possible confounders such as filter type and size, dialysis duration and alterations in sodium, standard bicarbonate and ionized calcium concentrations.
Our finding of a substantial clearance of insulin is in accordance with recent studies [7, [20] [21] [22] [23] . Abe et al. found polysulphone membranes to have the highest clearance of insulin and concluded that removal was mainly due to adsorption to the filters as no insulin was detected in the utilized dialysate [24] . In contrast, we were able to measure insulin in all dialysate samples and found that the relative removed solute from blood corresponded well to the relative amount found in the dialysate (HD: 40.0 versus 43.6%). This divergent result could partially be explained by the relative slow blood flow of 200 mL/min use by Abe et al., but the permeability of the used dialyser membrane and matrix (dialysate) interference of the immunoassay could also be important factors. Furthermore, the membrane used in the present study contained a mixture of polysulphone, polyvidone and polyamide polymers which may influence the electrochemical and hydrophilic/ hydrophobic properties and hence the ability to adsorb the proteins. Our results suggest that, with the current used membrane, insulin is cleared across the membrane both by diffusion and convection as indicated by the higher clearance during HDF.
Only few studies have examined the impact of dialysis on glucagon clearance and, to our knowledge, none in the recent decades. Jackson et al. found that the glucagon response to hypoglycaemia during dialysis was blunted, but whether this was attributed to an impaired hypoglycaemic response or glucagon removal was not investigated [25] . ESRD patients typically have glucagon levels 3-4 times higher than individuals with normal kidney function and the ability to suppress glucagon seems impaired [26] . Our results show that glucagon is cleared throughout the dialysis to a level very different from the habitual ( Figure 1D ). Hypoglycaemia has been reported during dialysis in the fasting state and with a glucose-free dialysate [25] , whereas it is rarely observed after treatment. Although speculative, this could indicate that the removed glucagon during dialysis mainly consists of inactive glucagonlike immunoreactive compounds [27] .
To our knowledge, only one study has previously reported plasma GLP-1 concentrations during dialysis. Fernández-Reyes et al. found increasing levels of intact GLP-1 during dialysis after a liquid mixed meal but, surprisingly also during parenteral supplementation and even in the fasting state [28] . The dialysis filters were the same as used in the present study, yet we found a decline in total GLP-1 concentration of 25% after 1 h of dialysis. The assays used to measure GLP-1 are known to be of varying specificity which together with a possible matrix effect may explain the counterintuitive elevating effect found by Fernández-Reyes et al. This could also explain our finding of a higher FA in dialysate than removed from the blood (HD: 18.2 versus 53.0%). Our finding of an apparent lesser clearance of GLP-1 is interesting since the MW of 3300 Da is very close to both C-peptide and glucagon (MW 3000 and 3500 Da), which were cleared considerably more.
Of the measured peptides, GIP was found to have the highest clearance, which was further augmented by HDF. In contrast to GLP-1, GIP has a MW of 5000 Da close to that of insulin (5800 Da). Interestingly, in a study from 1979, Owyang et al. found a 30% reduction in GIP concentrations after 6 h of HD [16] . Although not confirmed by others [15, 29] , this apparent clearance in low-flux filters suggests a potential significant adsorption of GIP to the dialyser membrane. This corresponds well with our findings that approximately half of the removed GIP was present in the utilized dialysate. Several studies have examined the postprandial response of glucoregulatory peptide hormones in ESRD patients, but only few were contrasted to the hormonal response during dialysis treatment. Fernández-Reyes et al. found an augmented insulin response during parenteral supplementation in contrast to enteral and concluded that the incretin effect was abolished during dialysis [28] . This finding, however, may be attributed to the rather large amount of insulin added to the parenteral supplementation. More recently, Czabak-Garbacz et al. showed that glucose administered through the dialysate yielded lower insulin concentrations than after an oral glucose tolerance test (OGTT) as expected [21] . We previously reported that the incretin effect, without dialysis, in non-diabetic ESRD patients accounted for about half of the insulin response to an OGTT [26] . Our present finding that insulin concentrations get lower by only 30-40% during dialysis also indicates some preservation of the incretin effect during dialysis especially considering the lower concentrations of the insulin-stimulating factors such as glucose, GLP-1 and GIP.
The clinical implications of our results should be interpreted with caution. The glucometabolic disturbances in ESRD are often associated with an impaired glucose tolerance [30] and therefore likely caused by an insufficient hormone response to meals. This is in spite of the often elevated concentrations of the glucose-lowering hormones (insulin, GLP-1 and GIP) observed in ESRD. A significant clearance of these hormones during dialysis may therefore aggravate this intolerance. In contrast, hyperglucagonaemia has been identified as an important contributor to postprandial hyperglycaemia in patients with type 2 diabetes and normal kidney function [31] . Our finding of a substantial clearance of glucagon with concentrations approaching normal levels could therefore have an anti-diabetic effect. As dialysis also seems to ameliorate the uraemic insulin resistance [6] , further studies are warranted to conclude on the net effect of dialysis on glucose metabolism.
There are some limitations to this study. We did not investigate patients with diabetes and did not distinguish between eventual impaired glucose tolerance and normal glucose tolerance. Even though parameters of solute removal during dialysis would not be expected to be affected by this, the post meal concentrations could be different in patients with ( pre) diabetes. Also, the possible influence of cardiopulmonary recirculation could have influenced solute concentration measurements but nor should that influence clearance. Finally, even though the relatively few patients with only four participating in the meal day were enough to draw statistical inference to our results, a generalization to the whole dialysis population should be done with caution.
In conclusion, we found that important glucoregulatory peptide hormones were removed during high-flux HD and high-volume HDF to a large extent by diffusion and/or convection. Furthermore, dialysis seemed to limit hormone concentrations as response to a meal. These novel effects of dialysis may affect the glucometabolic disturbances observed in dialysistreated ESRD patients.
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